Outcome of Board Meeting

Date: November 05, 2026 BSE Limited(“BSE”) National Stock Exchange of India Ltd(“NSE”) Phiroze Jeejeebhoy Towers Exchange Plaza 2nd Floor, Dalal Street Bandra-Kurla Complex, Bandra (E) Mumbai- 400001 Mumbai- 4000051 BSE Scrip Code: 544866 Symbol: MOLBIO Subject: Outcome of Board Meeting held on Thursday, November 05,2026 pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”). Dear Sir/Ma’am, Pursuant to Regulation 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("SEBI Listing Regulations") along with relevant SEBI circulars, as applicable, we wish to inform that the Board of Directors of Molbio Diagnostics Limited (“Company”), at its meeting held today i.e. Thursday, November 05, 2026 has, inter-alia, transacted the following businesses: 1. Approval of Un-audited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026. 2. The said Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half-year ended September 30, 2026, prepared in terms of Regulation 33 of the Listing Regulations together with Limited Review Report, are enclosed herewith as “Annexure-A”. The Company hereby declares that the Statutory Auditor have expressed an unmodified opinion in the Limited Review Report on the Financials Results for the quarter and half year ended September 30, 2026 under Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. 3. Approval of Monitoring Agency Report on the utilization of proceeds from the Initial Public Offer (IPO) of the company for the quarter ended September 30, 2026 pursuant to regulation 32 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as approved by the Audit Committee of the Company. 4. Noting of resignation of Dr. Kuldeep Singh Sachdeva, President & Chief Medical Officer, Senior Management Personnel (SMP) of the company. The disclosure as required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 as amended from time to time are enclosed here as “Annexure-B”. 5. Appointment of M/s. Rakesh Hulihalli & Associates, Practising Company Secretaries, a Peer Reviewed Firm (Certificate of Practice No. 16714), as the Secretarial Auditor of the Company for a term of five consecutive financial years commencing from FY 2026-27 and ending with FY 2030-31, subject to the approval of the members of the Company. The disclosure as required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 as amended from time to time are enclosed here as “Annexure-C”. 6. Approval of Notice of Postal Ballot through remote e-voting process and to authorise Director/KMP to decide the cut-off date and to dispatch the notice of Postal Ballot to the eligible members of the Company. The Board Meeting commenced at 03.36 P.M and concluded at 04.03 P.M. The above intimation is also available on the Company’s website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to kindly take the same on record. Thanking You. Yours Faithfully, For Molbio Diagnostics Limited Darshan Raghunath Karekar Company Secretary & Compliance Officer M.No: F13569 Date: November 05, 2026 Place: Verna-Goa Annexure A 11/4/26, 7:31 PM Inbox - Darshan Karekar - Outlook Annexure B From: Dr. Kuldeep Singh Sachdeva <drsachdevak@molbiodiagnostics.com> Sent: Thursday, October 22, 2026 12:13:26 pm To: Sriram Natarajan <nsriram@molbiodiagnostics.com> Subject: Tendering Resignation Dear Mr. Sriram, I hereby formally tender my resignation from the position of President and Chief Medical Officer, Partnerships and Advocacy at Molbio Diagnostics Limited. My last working day shall be 21 January 2027. I take this opportunity to acknowledge my tenure with the organization and wish for company continued success in future endeavors. Regards Dr Kuldeep Singh Sachdeva President & Chief Medical Officer Partnerships & Advocacy Molbio Diagnostics Ltd (formerly Molbio Diagnostics Pvt Ltd) Former NTP Manager/DDG CTD, Government of India Former HIV AIDS Manager/DDG NACO, Government of India Former Nodal Officer - India Country Coordination Mechanism (The Global Fund) Former Nodal Officer - Covid 19 Emergency Response & Health Systems Preparedness Former Regional Director, South East Asia, The Union Molbio Diagnostics Limited (Formerly Molbio Diagnostics Private Limited) https://outlook.cloud.microsoft/mail/id/AAkALgAAAAAAHYQDEapmEc2byACqAC%2FEWg0A7m%2BOO69ZEk6WViiWyq9GNgAAdlzHCAAA 2/2 Annexure- B The disclosure as required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 Sr. Particulars Details 1 Reason for change viz. appointment, Resignation reappointment, resignation, removal, death or otherwise 2 Date of appointment / re-appointment / Date of Resignation- October 22, 2026 cessation (as applicable) & term of appointment/re-appointment Cessation shall be effective from the closure of business hours on January 21, 2027 3 Brief profile (in case of appointment) Not Applicable 4 Disclosure of relationships between Not Applicable directors (in case of appointment of a director) Annexure- C The disclosure as required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 Sr. Particulars Details 1 Name M/s Rakesh Hulihalli & Associates, Practising Company Secretaries, a Peer Reviewed Firm (Certificate of Practice No. 16714) 2 Reason for change viz. Appointment as Secretarial Auditors of the Company for appointment, re-appointment, a first term of five (5) consecutive years commencing resignation, removal, death or from April 01, 2026 to March 31, 2031 pursuant to the otherwise; provisions of Section 204 of the Companies Act, 2013 and Regulation 24A of the SEBI(Listing Obligations and Disclosure Requirements),Regulation,2015. 3 Date of appointment/re- The Board of Directors at its meeting held on Thursday, appointment/cessation (as November 05,2026 approved the appointment of M/s applicable) & term of Rakesh Hulihalli & Associates, Practising Company appointment/re-appointment; Secretaries, a Peer Reviewed Firm (Certificate of Practice No. 16714 as Secretarial Auditors, for a period of five years commencing from FY 2026-27 till 2030-31 subject to approval of the shareholders. 4 Brief profile (in case of M/s. Rakesh Hulihalli & Associates, Practising appointment); Company Secretaries. The Firm provides professional services in the field of Company Laws, SEBI Regulations, FEMA Regulations including carrying out Secretarial Audits. The Firm is Peer Reviewed by the Institute of Company Secretaries of India. 5 Disclosure of relationships Not Applicable between directors (in case of appointment of a director).